Natera Inc (NTRA) USD0.0001

Sell:$138.71Buy:$138.82$2.86 (2.00%)

NASDAQ:5.97%
Market closed | Prices delayed by at least 15 minutes
Sell:$138.71
Buy:$138.82
Change:$2.86 (2.00%)
Market closed | Prices delayed by at least 15 minutes
Sell:$138.71
Buy:$138.82
Change:$2.86 (2.00%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.

Key people

Matthew Rabinowitz
Executive Chairman of the Board, Co-Founder
John Fesko
President, Chief Business Officer
Steven Leonard Chapman
Chief Executive Officer, Director
Jonathan Sheena
Co-Founder, Director
Michael Burkes Brophy
Chief Financial Officer
Solomon Moshkevich
President - Clinical Diagnostics
Daniel A Rabinowitz
Secretary, Chief Legal Officer
Roelof Frederick Botha
Lead Independent Director
Roy Baynes
Independent Director
Monica Bertagnolli
Independent Director
Rowan E. Chapman
Independent Director
James I. Healy
Independent Director
Click to see more

Key facts

  • EPIC
    NTRA
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US6323071042
  • Market cap
    $19.01bn
  • Employees
    4,424
  • Shares in issue
    135.19m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.